The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•18 February 2026•

1 min read

KalVista's EKTERLY Recommended as First-Line Therapy for Pediatric HAE in New Guidelines

KalVista Pharmaceuticals announced that its drug EKTERLY (sebetralstat) has been included in the newly published international guidelines as a first-line treatment for Hereditary Angioedema (HAE) attacks. The recommendation specifically covers the acute treatment of HAE attacks in adolescents aged 12 years and older, strengthening the drug's market position. This decision by the international committee is supported by robust, high-quality evidence from clinical trial data demonstrating the drug's efficacy and safety. Being recognized as a first-line therapy marks a significant commercial milestone that is expected to drive widespread adoption and improve insurance coverage. Analysts view this development as a positive driver for KalVista's long-term revenue potential within the biotechnology sector. Shares of KalVista Pharmaceuticals are currently traded on the Nasdaq under the ticker KALV.